kai 1

RKS262 is a specific cyclin CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.

KAI-11101 是一种双亮氨酸拉链激酶 (DLK, MAP3K12) 的抑制剂，Ki为 0.7 nM。它能够抑制Paclitaxel诱导的cJun磷酸化 (IC50=95 nM)，从而阻碍MAPK通路的激活。此外，KAI-11101 能穿透血脑屏障，这使其在神经保护特性方面具有进一步研究的潜力。

KAI-1678 is an inhibitor of epsilon protein kinase C (εPKC). KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.

Delcasertib acetate 是一种选择性 δ 蛋白激酶C (δPKC) 抑制剂，可用于研究急性心肌梗死和疼痛。

Delcasertib (KAI-9803) hydrochloride 是有效，选择性的 δ 蛋白激酶 C (δPKC) 抑制剂。Delcasertib (KAI-9803) hydrochloride 可改善急性心肌梗死动物模型的缺血再灌注损伤。